Price Disclosure Reductions for 2024 October Cycle
The 2024 October cycle has a data collection period of 1 October 2023 to 31 March 2024.
Responsible persons must have disclosed brand data to the Price Disclosure Data Administrator (PDDA) by the deadline of 13 May 2024.
The reduction day is 1 October 2024.
Responsible persons should ensure that their authorised representatives keep their details up to date via the Health Products Portal, and sign up to the PBS Newsletter.
Contents
- Outcomes of Price Disclosure calculations
- Indicative prices of brands scheduled for a price disclosure reduction
- Confirmed prices of brands scheduled for a price disclosure reduction
- Brand price reductions and savings to patients
Outcomes of Price Disclosure calculations
The PDDA calculates weighted average disclosed prices (WADPs) to be provided to the Department of Health and Aged Care. The Minister determines WADPs calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).
The outcomes reflecting these determinations have been published in a legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their April 2024 PBS approved ex‑manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 31 March 2024 will also take the reduction on 1 October 2024 under section 99ADHA of the Act.
Please note an agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The deadline to lodge a dispute is 23 July 2024.
A list of pharmaceutical items scheduled for a price disclosure reduction and their weighted average disclosed prices is presented in the table below.
| Legal Instrument Drug | Legal Instrument Form | Legal Instrument MoA | Brands of PI designated brands under 99ADHC (Y/N) | Floor Price | Price reduction applied in 2 previous cycles (Y/N) | Average Unadjusted Price Reduction (UPR) exceeds 12.5% over 3 cycles (Y/N) | April 2024 AEMP | October 2024 AEMP | Percentage difference between April 2024 and October 2024 AEMP (%) | UPR threshold (%) |
Calculations based on: OWAPD = all brand data GWAPD = originator brand data removed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aciclovir | Tablet 200 mg | Oral | Y | $5.54 | N | Y | $5.54 | $4.70 | 15.16% | 10.00% | OWAPD |
| Aciclovir | Tablet 800 mg | Oral | Y | $24.12 | N | Y | $24.12 | $20.48 | 15.09% | 10.00% | OWAPD |
| Ambrisentan | Tablet 10 mg | Oral | N | - | - | - | $1,652.15 | $1,381.53 | 16.38% | 10.00% | GWAPD |
| Ambrisentan | Tablet 5 mg | Oral | N | - | - | - | $1,652.15 | $1,381.53 | 16.38% | 10.00% | GWAPD |
| Amisulpride | Tablet 100 mg | Oral | Y | $5.50 | N | Y | $5.50 | $4.75 | 13.64% | 10.00% | GWAPD |
| Amisulpride | Tablet 200 mg | Oral | Y | $23.72 | N | Y | $23.72 | $20.48 | 13.66% | 10.00% | GWAPD |
| Amisulpride | Tablet 400 mg | Oral | Y | $43.01 | N | Y | $43.01 | $37.14 | 13.65% | 10.00% | GWAPD |
| Azathioprine | Tablet 25 mg | Oral | Y | $9.32 | N | Y | $9.32 | $7.80 | 16.31% | 10.00% | GWAPD |
| Azathioprine | Tablet 50 mg | Oral | Y | $15.88 | N | Y | $15.88 | $13.29 | 16.31% | 10.00% | GWAPD |
| Bendamustine | Powder for injection containing bendamustine hydrochloride 100 mg | Injection | N | - | - | - | $575.21 | $124.07 | 78.43% | 10.00% | OWAPD |
| Bendamustine | Powder for injection containing bendamustine hydrochloride 25 mg | Injection | N | - | - | - | $143.81 | $31.02 | 78.43% | 10.00% | OWAPD |
| Bevacizumab | Solution for I.V. infusion 100 mg in 4 mL | Injection | N | - | - | - | $90.32 | $61.77 | 31.61% | 10.00% | OWAPD |
| Bevacizumab | Solution for I.V. infusion 400 mg in 16 mL | Injection | N | - | - | - | $361.27 | $247.07 | 31.61% | 10.00% | OWAPD |
| Bortezomib | Powder for injection 2.5 mg | Injection | N | - | - | - | $55.34 | $28.47 | 48.55% | 10.00% | OWAPD |
| Bortezomib | Powder for injection 3.5 mg | Injection | N | - | - | - | $77.47 | $39.85 | 48.56% | 10.00% | OWAPD |
| Bortezomib | Solution for injection 2.5 mg in 1 mL | Injection | N | - | - | - | $55.34 | $28.47 | 48.55% | 10.00% | OWAPD |
| Bortezomib | Solution for injection 3.5 mg in 1.4 mL | Injection | N | - | - | - | $77.47 | $39.85 | 48.56% | 10.00% | OWAPD |
| Clopidogrel with aspirin | Tablet 75 mg (as hydrogen sulfate)-100 mg | Oral | Y | $4.07 | N | Y | $4.07 | $4.00 | 1.72% | 10.00% | OWAPD |
| Clozapine | Tablet 100 mg | Oral | Y | $121.19 | N | Y | $121.19 | $104.04 | 14.15% | 10.00% | GWAPD |
| Clozapine | Tablet 200 mg | Oral | Y | $242.38 | N | Y | $242.38 | $208.08 | 14.15% | 10.00% | GWAPD |
| Clozapine | Tablet 25 mg | Oral | Y | $32.32 | N | Y | $32.32 | $27.75 | 14.14% | 10.00% | GWAPD |
| Clozapine | Tablet 50 mg | Oral | Y | $64.64 | N | Y | $64.64 | $55.49 | 14.16% | 10.00% | GWAPD |
| Dasatinib | Tablet 100 mg | Oral | N | - | - | - | $1,770.45 | $1,197.56 | 32.36% | 10.00% | OWAPD |
| Dasatinib | Tablet 20 mg | Oral | N | - | - | - | $1,074.89 | $727.08 | 32.36% | 10.00% | OWAPD |
| Dasatinib | Tablet 50 mg | Oral | N | - | - | - | $1,770.45 | $1,197.56 | 32.36% | 10.00% | OWAPD |
| Dasatinib | Tablet 70 mg | Oral | N | - | - | - | $2,191.93 | $1,482.66 | 32.36% | 10.00% | OWAPD |
| Desvenlafaxine | Tablet (extended release) 100 mg (as succinate) | Oral | Y | $9.42 | N | Y | $9.42 | $7.92 | 15.92% | 10.00% | OWAPD |
| Desvenlafaxine | Tablet (extended release) 50 mg (as succinate) | Oral | Y | $7.67 | N | Y | $7.67 | $6.45 | 15.91% | 10.00% | OWAPD |
| Desvenlafaxine | Tablet (modified release) 100 mg | Oral | Y | $9.42 | N | Y | $9.42 | $7.92 | 15.92% | 10.00% | OWAPD |
| Desvenlafaxine | Tablet (modified release) 100 mg (as benzoate) | Oral | Y | $9.42 | N | Y | $9.42 | $7.92 | 15.92% | 10.00% | OWAPD |
| Desvenlafaxine | Tablet (modified release) 50 mg | Oral | Y | $7.67 | N | Y | $7.67 | $6.45 | 15.91% | 10.00% | OWAPD |
| Desvenlafaxine | Tablet (modified release) 50 mg (as benzoate) | Oral | Y | $7.67 | N | Y | $7.67 | $6.45 | 15.91% | 10.00% | OWAPD |
| Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg | Oral | Y | $6.25 | N | Y | $6.25 | $5.39 | 13.76% | 10.00% | GWAPD |
| Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 240 mg | Oral | Y | $8.45 | N | Y | $8.45 | $7.29 | 13.73% | 10.00% | GWAPD |
| Dimethyl fumarate | Capsule (modified release) 120 mg | Oral | N | - | - | - | $154.25 | $114.62 | 25.69% | 10.00% | GWAPD |
| Dimethyl fumarate | Capsule (modified release) 240 mg | Oral | N | - | - | - | $594.89 | $392.81 | 33.97% | 10.00% | GWAPD |
| Fenofibrate | Tablet 145 mg | Oral | Y | $8.48 | N | Y | $8.48 | $6.95 | 18.04% | 10.00% | GWAPD |
| Fenofibrate | Tablet 48 mg | Oral | Y | $5.66 | N | Y | $5.66 | $4.64 | 18.02% | 10.00% | GWAPD |
| Filgrastim | Injection 300 micrograms in 0.5 mL single-use pre-filled syringe | Injection | Y | $71.97 | N | Y | $71.97 | $58.73 | 18.40% | 10.00% | GWAPD |
| Filgrastim | Injection 480 micrograms in 0.5 mL single-use pre-filled syringe | Injection | Y | $115.36 | N | Y | $115.36 | $94.15 | 18.39% | 10.00% | GWAPD |
| Fingolimod | Capsule 500 micrograms (as hydrochloride) | Oral | N | - | - | - | $951.05 | $829.79 | 12.75% | 10.00% | OWAPD |
| Flecainide | Tablet containing flecainide acetate 100 mg | Oral | N | - | - | - | $18.52 | $15.98 | 13.71% | 10.00% | GWAPD |
| Flecainide | Tablet containing flecainide acetate 50 mg | Oral | N | - | - | - | $14.94 | $12.89 | 13.72% | 10.00% | GWAPD |
| Fulvestrant | Injection 250 mg in 5 mL pre-filled syringe | Injection | N | - | - | - | $193.73 | $164.59 | 15.04% | 10.00% | OWAPD |
| Gabapentin | Capsule 300 mg | Oral | Y | $10.69 | N | Y | $10.69 | $8.97 | 16.09% | 10.00% | GWAPD |
| Gabapentin | Capsule 400 mg | Oral | Y | $14.57 | N | Y | $14.57 | $12.23 | 16.06% | 10.00% | GWAPD |
| Gabapentin | Tablet 800 mg | Oral | Y | $30.83 | N | Y | $30.83 | $25.88 | 16.06% | 10.00% | GWAPD |
| Ganirelix | Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe | Injection | N | - | - | - | $28.76 | $24.77 | 13.87% | 10.00% | GWAPD |
| Glatiramer | Injection containing glatiramer acetate 40 mg in 1 mL single dose pre-filled pen | Injection | N | - | - | - | $584.71 | $522.96 | 10.56% | 10.00% | GWAPD |
| Glatiramer | Injection containing glatiramer acetate 40 mg in 1 mL single dose pre-filled syringe | Injection | N | - | - | - | $549.71 | $491.66 | 10.56% | 10.00% | GWAPD |
| Icatibant | Injection 30 mg (as acetate) in 3 mL single use pre-filled syringe | Injection | N | - | - | - | $749.33 | $579.16 | 22.71% | 10.00% | OWAPD |
| Lacosamide | Tablet 100 mg | Oral | N | - | - | - | $20.13 | $16.57 | 17.69% | 10.00% | OWAPD |
| Lacosamide | Tablet 150 mg | Oral | N | - | - | - | $30.18 | $24.85 | 17.66% | 10.00% | OWAPD |
| Lacosamide | Tablet 200 mg | Oral | N | - | - | - | $160.98 | $132.53 | 17.67% | 10.00% | OWAPD |
| Lacosamide | Tablet 50 mg | Oral | N | - | - | - | $10.06 | $8.28 | 17.69% | 10.00% | OWAPD |
| Lamivudine | Tablet 100 mg | Oral | Y | $26.75 | N | Y | $26.75 | $23.44 | 12.37% | 10.00% | GWAPD |
| Lamivudine | Tablet 150 mg | Oral | Y | $50.50 | N | Y | $50.50 | $44.26 | 12.36% | 10.00% | GWAPD |
| Lamivudine | Tablet 300 mg | Oral | Y | $50.50 | N | Y | $50.50 | $44.26 | 12.36% | 10.00% | GWAPD |
| Lenalidomide | Capsule 10 mg | Oral | N | - | - | - | $886.72 | $669.88 | 24.45% | 10.00% | OWAPD |
| Lenalidomide | Capsule 15 mg | Oral | N | - | - | - | $1,067.96 | $806.80 | 24.45% | 10.00% | OWAPD |
| Lenalidomide | Capsule 25 mg | Oral | N | - | - | - | $1,397.25 | $1,055.57 | 24.45% | 10.00% | OWAPD |
| Lenalidomide | Capsule 5 mg | Oral | N | - | - | - | $676.86 | $511.34 | 24.45% | 10.00% | OWAPD |
| Macrogol 3350 | Sachets containing powder for oral solution 13.125 g with electrolytes, 30 | Oral | Y | $7.04 | N | Y | $7.04 | $5.83 | 17.19% | 10.00% | GWAPD |
| Morphine | Injection containing morphine hydrochloride trihydrate 100 mg in 5 mL | Injection | N | - | - | - | $18.80 | $16.91 | 10.05% | 10.00% | OWAPD |
| Moxonidine | Tablet 200 micrograms | Oral | Y | $5.06 | N | Y | $5.06 | $4.22 | 16.60% | 10.00% | GWAPD |
| Moxonidine | Tablet 400 micrograms | Oral | Y | $8.62 | N | Y | $8.62 | $7.19 | 16.59% | 10.00% | GWAPD |
| Naloxone | Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule | Injection | Y | $20.56 | N | Y | $20.56 | $16.22 | 21.11% | 10.00% | OWAPD |
| Olanzapine | Tablet 10 mg | Oral | Y | $7.55 | N | Y | $7.55 | $6.34 | 16.03% | 10.00% | GWAPD |
| Olanzapine | Tablet 10 mg (orally disintegrating) | Oral | Y | $7.55 | N | Y | $7.55 | $6.34 | 16.03% | 10.00% | GWAPD |
| Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | Y | $11.33 | N | Y | $11.33 | $9.52 | 15.98% | 10.00% | GWAPD |
| Olanzapine | Tablet 20 mg (orally disintegrating) | Oral | Y | $15.11 | N | Y | $15.11 | $12.69 | 16.02% | 10.00% | GWAPD |
| Olanzapine | Tablet 7.5 mg | Oral | Y | $5.67 | N | Y | $5.67 | $4.76 | 16.05% | 10.00% | GWAPD |
| Olanzapine | Wafer 10 mg | Oral | Y | $7.55 | N | Y | $7.55 | $6.34 | 16.03% | 10.00% | GWAPD |
| Olanzapine | Wafer 15 mg | Oral | Y | $11.33 | N | Y | $11.33 | $9.52 | 15.98% | 10.00% | GWAPD |
| Olanzapine | Wafer 20 mg | Oral | Y | $15.11 | N | Y | $15.11 | $12.69 | 16.02% | 10.00% | GWAPD |
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) | Oral | N | - | - | - | $6.39 | $5.56 | 12.99% | 10.00% | GWAPD |
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) | Oral | N | - | - | - | $5.96 | $5.18 | 13.09% | 10.00% | GWAPD |
| Pegfilgrastim | Injection 6 mg in 0.6 mL single use pre-filled syringe | Injection | Y | $118.44 | N | Y | $118.44 | $91.63 | 22.64% | 10.00% | OWAPD |
| Pirfenidone | Tablet 267 mg | Oral | N | - | - | - | $177.05 | $150.26 | 15.13% | 10.00% | OWAPD |
| Pirfenidone | Tablet 801mg | Oral | N | - | - | - | $531.17 | $450.80 | 15.13% | 10.00% | OWAPD |
| Pomalidomide | Capsule 2 mg | Oral | N | - | - | - | $1,243.81 | $1,108.61 | 10.87% | 10.00% | OWAPD |
| Pomalidomide | Capsule 3 mg | Oral | N | - | - | - | $1,865.72 | $1,662.92 | 10.87% | 10.00% | OWAPD |
| Pomalidomide | Capsule 4 mg | Oral | N | - | - | - | $2,487.62 | $2,217.22 | 10.87% | 10.00% | OWAPD |
| Posaconazole | Tablet (modified release) 100 mg | Oral | N | - | - | - | $136.60 | $104.77 | 23.30% | 10.00% | OWAPD |
| Pregabalin | Capsule 150 mg | Oral | Y | $9.20 | N | Y | $9.20 | $7.19 | 21.85% | 10.00% | GWAPD |
| Pregabalin | Capsule 300 mg | Oral | Y | $13.72 | N | Y | $13.72 | $10.72 | 21.87% | 10.00% | GWAPD |
| Pregabalin | Capsule 75 mg | Oral | Y | $5.99 | N | Y | $5.99 | $4.68 | 21.87% | 10.00% | GWAPD |
| Quetiapine | Tablet (modified release) 150 mg (as fumarate) | Oral | Y | $11.11 | N | Y | $11.11 | $9.55 | 14.04% | 10.00% | GWAPD |
| Quetiapine | Tablet (modified release) 200 mg (as fumarate) | Oral | Y | $22.87 | N | Y | $22.87 | $19.65 | 14.08% | 10.00% | GWAPD |
| Quetiapine | Tablet (modified release) 300 mg (as fumarate) | Oral | Y | $29.37 | N | Y | $29.37 | $25.23 | 14.10% | 10.00% | GWAPD |
| Quetiapine | Tablet (modified release) 400 mg (as fumarate) | Oral | Y | $40.04 | N | Y | $40.04 | $34.40 | 14.09% | 10.00% | GWAPD |
| Quetiapine | Tablet (modified release) 50 mg (as fumarate) | Oral | Y | $7.86 | N | Y | $7.86 | $6.75 | 14.12% | 10.00% | GWAPD |
| Quetiapine | Tablet 100 mg (as fumarate) | Oral | Y | $11.11 | N | Y | $11.11 | $9.55 | 14.04% | 10.00% | GWAPD |
| Quetiapine | Tablet 200 mg (as fumarate) | Oral | Y | $15.14 | N | Y | $15.14 | $13.01 | 14.07% | 10.00% | GWAPD |
| Quetiapine | Tablet 300 mg (as fumarate) | Oral | Y | $22.23 | N | Y | $22.23 | $19.10 | 14.08% | 10.00% | GWAPD |
| Rasagiline | Tablet 1 mg (as mesilate) | Oral | N | - | - | - | $26.29 | $18.67 | 28.98% | 10.00% | GWAPD |
| Tenofovir | Tablet containing tenofovir disoproxil maleate 300 mg | Oral | Y | $77.46 | Y | Y | $77.46 | $53.38 | 31.09% | 30.00% | GWAPD |
| Tenofovir | Tablet containing tenofovir disoproxil phosphate 291 mg | Oral | Y | $77.46 | Y | Y | $77.46 | $53.38 | 31.09% | 30.00% | GWAPD |
| Terbinafine | Tablet 250 mg (as hydrochloride) | Oral | Y | $14.29 | N | Y | $14.29 | $11.88 | 16.86% | 10.00% | GWAPD |
| Teriflunomide | Tablet 14 mg | Oral | Y | $151.76 | Y | Y | $151.76 | $96.50 | 36.41% | 30.00% | OWAPD |
| Valsartan | Tablet 160 mg | Oral | Y | $7.47 | N | Y | $7.47 | $6.39 | 14.46% | 10.00% | GWAPD |
| Valsartan | Tablet 320 mg | Oral | Y | $9.58 | N | Y | $9.58 | $8.19 | 14.51% | 10.00% | GWAPD |
| Valsartan | Tablet 80 mg | Oral | Y | $5.82 | N | Y | $5.82 | $4.98 | 14.43% | 10.00% | GWAPD |
| Vinorelbine | Capsule 20 mg (as tartrate) | Oral | N | - | - | - | $72.12 | $46.05 | 36.15% | 10.00% | GWAPD |
| Vinorelbine | Capsule 30 mg (as tartrate) | Oral | N | - | - | - | $108.80 | $69.47 | 36.15% | 10.00% | GWAPD |
| Voriconazole | Tablet 200 mg | Oral | Y | $264.04 | Y | Y | $264.04 | $168.54 | 36.17% | 30.00% | GWAPD |
| Voriconazole | Tablet 50 mg | Oral | Y | $66.01 | Y | Y | $66.01 | $42.13 | 36.18% | 30.00% | GWAPD |
| Ziprasidone | Capsule 20 mg (as hydrochloride) | Oral | Y | $32.62 | N | Y | $32.62 | $27.51 | 15.67% | 10.00% | OWAPD |
| Ziprasidone | Capsule 40 mg (as hydrochloride) | Oral | Y | $65.36 | N | Y | $65.36 | $55.12 | 15.67% | 10.00% | OWAPD |
| Ziprasidone | Capsule 60 mg (as hydrochloride) | Oral | Y | $97.68 | N | Y | $97.68 | $82.37 | 15.67% | 10.00% | OWAPD |
| Ziprasidone | Capsule 80 mg (as hydrochloride) | Oral | Y | $130.42 | N | Y | $130.42 | $109.98 | 15.67% | 10.00% | OWAPD |
Flow-on price disclosure reductions
A list of brands of pharmaceutical items that will be subject to an automatic flow-on price disclosure reduction under section 99ADHB of the National Health Act 1953 on 1 October 2024 is available in the Pricing-Combination-Flow-on-Price-Reductions-FED-1-Oct-2024 (Excel 12 KB). Sponsors were able to apply for Ministerial discretion for these reductions to be reduced or not apply. For more information see Ministerial Discretion.
Confirmed prices of brands scheduled for a price disclosure reduction
The Confirmed Prices Reports outlines the approved ex‑manufacturer price for brands scheduled to take a price disclosure reduction. The reports for the 2024 October cycle can be downloaded below.
Brand price reductions and savings to patients
The Brand Price Reductions and Savings to Patients Report outlines the price disclosure reductions per brand and potential savings to non-concessional patients from 1 October 2024. This information is made available to assist patients understand how much they may save on their PBS medicines.
The report does not include any brands of medicines that have other price changes, or brands that are new to the PBS on the reduction day.
The brand price reductions report for the 2024 October cycle can be downloaded below.